In early April 2026, against the backdrop of the "15th Five-Year Plan" designating biomanufacturing as a core future industry, Hangzhou Yuhuangshan South Fund Town, Gaorong Venture Capital, and the international venture capital ecosystem service platform CYzone jointly launched the "Biomanufacturing" Institutional Day Summit. The event invited leading companies and investment community friends to gather at the beautiful Hangzhou Yuhuangshan South Fund Town to discuss "The Industrialization Path and Commercial Application Breakthroughs of Biomanufacturing." As a representative of AI-driven high-end protein innovation platform companies, Yinjia Bio was invited to attend. Dr. Wu Yifei, Founder and CEO, delivered a keynote speech titled "Technology Breakthroughs Based on First Principles and Commercialization Challenges," systematically explaining how the "Five-Step" theory based on first principles fundamentally addresses the efficiency and cost bottlenecks in biomanufacturing, enabling accelerated R&D closed-loop iteration and commercialization breakthroughs. He engaged in discussions and exchanges with industry peers.
In his keynote, Dr. Wu also introduced how Yinjia Bio, guided by first principles, has constructed a systematic "Five-Step" application framework covering the entire chain from metabolic bottleneck analysis and AI-assisted protein design to cell-free rapid prototyping, process scale-up, and commercial adaptation. This framework enables efficient closed-loop iteration between AI predictive capabilities and wet-lab validation. Guided by this framework, the company has developed a micro-scale cell-free protein expression system suitable for high-throughput screening, capable of efficiently expressing various proteins in a reaction system of<10µl.With the experimental validation of this novel cell-free protein expression system on the novel Turing protein chip, it can significantly shorten the closed-loop cycle of "AI protein design - high-throughput experimental validation - redesign," elevating novel protein development efficiency to new heights.
Gaorong Venture Capital is one of Yinjia Bio's early lead investors and a co-organizer of this event. During the summit, Dr. Yue Beilin, Managing Director of Gaorong Venture Capital, shared his analysis of the biomanufacturing industry's development prospects and investment philosophy. He also pointed out that as AI technology platforms continuously innovate, the connection between AI technology and the biomanufacturing industry is becoming increasingly close. Yinjia Bio's thematic presentation at this event fully demonstrated the company's core technological advantages and the "powerful synergy" achieved with its AI platform, highlighting the benchmark value of AI+ in empowering the biomanufacturing sector.
In the subsequent roundtable discussion, representatives from innovative companies such as HuiGene, Gas-to-Chemicals, Evolution Silicon, and CreaGene also shared cutting-edge insights from perspectives like technological positioning and commercialization choices, collectively outlining a diversified development landscape for the biomanufacturing industry.
As the "15th Five-Year Plan" clearly positions biomanufacturing as a new economic growth driver, the deep integration of AI and biomanufacturing is evolving from an "auxiliary tool" to a "core driving force." Yinjia Bio will continue to leverage the industrial resources of leading investment institutions like Gaorong Venture Capital to accelerate the flywheel effect of AI design - protein manufacturing - commercial application, striving to become a leader in AI-driven innovative proteins.
Prev